ADH has a particularly substantial risk for breast cancer when coupled with BIRADS IV/V and large breast tissue volume. ADH on core biopsy may perhaps symbolize inadequately sampled DCIS. Tumor agnostic regulatory approvals can be found for neurotrophic receptor TKI and for pembrolizumab in M